Although identified CHEK2 mutations suggested that CHEK2 is a candidate tumor suppressor in various types of cancer, such as breast cancer (62, 63), recent evidence showed that CHEK2 might also act as an oncogene shaping the response to chemotherapy (64, 65) and checkpoint kinase inhibitors have shown promise as therapeutic agents (66, 67). Here, CHEK2 is linked to neoplasm.